Table 6.

Highlights the drugs commonly associated with DISR.

	Drug class	Percentage of patients requiring anti-sarcoidosis treatment	References
1.	Interferon (interferon alpha and interferon beta)	42.9% (157)	(164, 166–168)
2.	Tumor necrosis factor-α antagonist	59.5% (157)	(169, 170)
3.	BRAF inhibitor	0%	(171, 172)
4.	Interleukin-1 receptor antagonist	0%	(173)
5.	Immune checkpoint inhibitors (nivolumab, pembrolizumab, ipilimumab)	57.2% (157)	(174, 175)
6.	Highly active antiretroviral therapy (HAART)	41.1% (157)	(176–178)
7.	Botulinum neurotoxin A	0% (157)	(179)